News | FDA | August 18, 2023

Abiomed Recalls the Labeling for Impella RP Flex with SmartAssist for Risk of Blood Clots

Abiomed is recalling the labeling for Impella RP Flex with Smart Assist System Catheter because the catheters’ Instructions for Use (IFU) do not appropriately address precautions for healthcare providers to take when treating patients whose anticoagulation clotting time is below the recommended value 

Abiomed is recalling the labeling for Impella RP Flex with Smart Assist System Catheter

August 18, 2023 — The U.S. Food and Drug Administration (FDA) announced that Abiomed is recalling the labeling for Impella RP Flex with Smart Assist System Catheter because the catheters’ Instructions for Use (IFU) do not appropriately address precautions for health care providers to take when treating patients whose anticoagulation clotting time is below the recommended value. Patients with central venous lines and cardiac cannulas with systemic anticoagulation below IFU recommendation of 160-180 seconds are most at risk. 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 

Please be aware, this recall is a voluntary correction, not a product removal. 

Recalled Product 

  • Product Names: Impella RP Flex with SmartAssist 
  • Product Codes: See Recall Database Entry 
  • Model Number: 1000323 
  • Distribution Dates: November 1, 2022 to present 
  • Devices Recalled in the U.S.: 65 
  • Date Initiated by Firm: June 29, 2023 

Device Use 

The Impella RP Flex with Smart Assist System Catheter is used for up to 14 days in patients that develop acute right heart failure after left ventricular assist device implantation. The device is placed via the internal jugular vein and supports the right chamber of the heart (ventricle) by pumping blood into the pulmonary artery. 

Reason for Recall 

Abiomed is recalling the labeling for Impella RP Flex with Smart Assist System Catheter because the catheters' Instructions for Use (IFU) do not appropriately address precautions for health care providers to take when treating patients whose anticoagulation clotting time is below the recommended value. Patients with central venous lines and cardiac cannulas with systemic anticoagulation below IFU recommendation of 160-180 seconds are most at risk. 

Please note that clinicians may continue to use the devices. The use of affected catheters may cause serious adverse health consequences including the risk of blood clots or particle deposits forming or death. 

There have been 12 reported injuries. There have been no reports of death. 

Who May be Affected 

  • People who receive circulatory support from Impella RP Flex with SmartAssist Catheters 
  • Health care personnel providing care for people who receive support using the Impella RP Flex with SmartAssist Catheters 

What to Do 

On June 29, 2023, Abiomed sent all affected customers an Important Medical Device Advisory letter. 

To minimize risk of thrombus formation or deposition, the following is recommended: 

  • Maintain systemic anticoagulation (ACTs of 160-180 seconds) when indwelling central venous lines (i.e., hemodialysis, PA catheters) are present, for the duration of Impella® RP Flex with SmartAssist support as clinically feasible. 
  • Assess the risk for extraluminal thrombus on indwelling lines (i.e., hemodialysis catheters, PA catheters) placed prior to initiation of support. 
  • Refer to the recommendations included in the "best practices pathway" on Figure 5.2 of IFU for optimal patient selection. In particular, elements that relate to the risk factors identified above: 
    • Evidence of end-organ failure (bilirubin >5 or creatinine >4 within 24 hours of implant) 
    • Active infection (two of the following three: White Blood Cell (WBC) count >12,500, positive blood culture or fever) 
    • Documented Deep Vein Thrombosis (DVT) 
    • Patients on right-sided support or Extracorporeal Membrane Oxygenation (ECMO) 

Abiomed is revising the IFUs for the Impella® RP Flex with SmartAssist to clarify the risk factors and recommendations related to the potential of thrombus formation or deposition. 

 

Contact Information 

Customers with questions about this recall should contact Abiomed's Clinical Support Center at 1-800-422-8666. 

Additional Resources 

Medical Device Recalls database 

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX. 

Related content: 

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure 

Henry Ford Health Cardiologists First in Michigan to Use Heart Recovery Technology 

Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation 


Related Content

News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
Subscribe Now